Maraviroc is indicated for treatment of HIV infection. Maraviroc is a chemokine receptor antagonist that prevents HIV infection of CD4 T-cells by blocking the CCR5 receptor. The antiviral mechanism of action of maraviroc is exclusively CCR5-mediated by preventing the interaction of HIV-1 glycoprotein (gp)120 and CCR5 necessary for CCR5-tropic HIV-1 to enter cells. It is inactive against the CXCR4 receptor, and does not inhibit dual-tropic HIV-1 entry.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API).
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL monograph for Maraviroc, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.